Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Oncolytics Biotech Inc. (ONCY : NSDQ)

• Company Description    Oncolytics Biotech, Inc. focuses on the discovery and development of pharmaceutical products for the treatment of a wide variety of human and companion pet cancers. The Company was formed to explore the oncolytic capability of the reovirus, a virus that preferentially replicates in cells with an activated Ras pathway, one of the most common family of genetic defects leading to cancer. Number of Employees: 28

• Price / Volume Information    Yesterday's Closing Price: $1.20 Daily Weekly Monthly 20 Day Moving Average: 1,042,953 shares Shares Outstanding: 100.36 (millions) Market Capitalization: $120.43 (millions) Beta: 1.24 52 Week High: $1.51 52 Week Low: $0.33 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -6.25% -5.80% 12 Week -5.51% -9.20% Year To Date 31.32% 17.88%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 804 322 - 11 AVENUE SW - CALGARY,A0 T2R 0C5 CAN ph: 403-670-7380 fax: 403-283-0858 jpatton@oncolytics.ca http://www.oncolyticsbiotech.com

• General Corporate Information    Officers Wayne Pisano - Interim Chief Executive Officer and Chairman Kirk Look - Chief Financial Officer Allison Hagerman - Vice President Christophe Degois - Vice President Deborah M. Brown - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 682310875 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/11/25 Share - Related Items Shares Outstanding: 100.36 Most Recent Split Date: 5.00 (0.11:1) Beta: 1.24 Market Capitalization: $120.43 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.06 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.28 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/11/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 26.55 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 28.57% vs. Previous Quarter: 16.67% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 09/30/25 - - 06/30/25 - -438.11 03/31/25 - -313.77 ROA 09/30/25 - - 06/30/25 - -143.90 03/31/25 - -130.19 Current Ratio 09/30/25 - - 06/30/25 - 2.88 03/31/25 - 3.20 Quick Ratio 09/30/25 - - 06/30/25 - 2.88 03/31/25 - 3.20 Operating Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Net Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Pre-Tax Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Book Value 09/30/25 - - 06/30/25 - 0.05 03/31/25 - 0.05 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00

Powered by Zacks Investment Research ©